Plain-English translation of NCT04876781 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a safety and effectiveness study of Xeljanz XR, a medication used to treat three types of inflammatory arthritis: rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Researchers in Korea want to monitor how well the medication works and what side effects people experience over 6 months when taking it as part of their regular medical care. This helps doctors understand how the medication performs in real-world situations outside of controlled research settings.
Regulatory agencies require ongoing monitoring of medications after they're approved and available to patients. This study gathers safety and effectiveness data from actual patients using the medication in Korea to make sure it continues to work well and remains safe for the people who need it.
You likely qualify if…
You likely don't qualify if…
You would continue taking the medication as your doctor normally prescribes it, but you would also be monitored closely by the research team for 6 months. During this time, you would have visits where researchers check for any side effects, ask about your symptoms, and perform blood tests to measure how well the medication is controlling your arthritis. The study tracks changes in your joint pain, swelling, and overall disease activity using standard health assessments.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
South Korea
Sponsor
Pfizer
Enrollment target
~200 participants
Started
January 2022
Primary completion
June 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pfizer CT.gov Call Center
Pfizer
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.